Baseline characteristics of patients with ≥VGPR and <VGPR after 2 cycles of first-line treatment
| Baseline characteristics . | ≥VGPR after 2 cycles (N = 240) . | <VGPR after 2 cycles (N = 600) . | P . |
|---|---|---|---|
| Age, median (range), y | 63 (27-90) | 64 (28-92) | .6 |
| Age ≥70 y, n (%) | 59 (25) | 171 (29) | .3 |
| Males, n (%) | 152 (63) | 334 (56) | .04 |
| Light chain disease, n (%) | 105 (44) | 118 (20) | <.001 |
| ISS stage III | 69/175 (39) | 119/445 (27) | .002 |
| Hemoglobin <10 g/dL | 81/229 (36) | 152/547 (28) | .04 |
| Creatinine ≥2 mg/dL | 48/226 (21) | 48/539 (9) | <.001 |
| Calcium ≥11 mg/dL | 21/219 (10) | 27/533 (5) | .03 |
| β2 microglobulin >5.5 μg/mL | 76/202 (38) | 133/463 (29) | .02 |
| Albumin ≤3.5 g/dL | 113/192 (59) | 252/520 (49) | .01 |
| Lactate dehydrogenase >222 U | 27/166 (16) | 59/445 (13) | .4 |
| BMPCs ≥50% | 129/231 (56) | 282/541 (52) | .3 |
| PCLI ≥1% | 50/101 (50) | 125/296 (42) | .2 |
| FISH | |||
| Trisomies | 75/165 (46) | 288/454 (63) | <.001 |
| 17p deletion/monosomy 17 | 18/165 (11) | 50/454 (11) | .97 |
| t(4;14) | 22/165 (13) | 32/454 (7) | .02 |
| t(14;16) | 8/165 (5) | 21/454 (5) | .9 |
| High-risk FISH | 46/165 (28) | 88/454 (19) | .03 |
| First-line treatment, n (%) | |||
| Doublet/triplet/other | 77/149/14 (32/62/6) | 299/247/54 (50/41/9) | <.001 |
| PI-based therapy | 158 (66) | 213 (36) | <.001 |
| ASCT in first-line therapy | 131 (55) | 280 (47) | .03 |
| Baseline characteristics . | ≥VGPR after 2 cycles (N = 240) . | <VGPR after 2 cycles (N = 600) . | P . |
|---|---|---|---|
| Age, median (range), y | 63 (27-90) | 64 (28-92) | .6 |
| Age ≥70 y, n (%) | 59 (25) | 171 (29) | .3 |
| Males, n (%) | 152 (63) | 334 (56) | .04 |
| Light chain disease, n (%) | 105 (44) | 118 (20) | <.001 |
| ISS stage III | 69/175 (39) | 119/445 (27) | .002 |
| Hemoglobin <10 g/dL | 81/229 (36) | 152/547 (28) | .04 |
| Creatinine ≥2 mg/dL | 48/226 (21) | 48/539 (9) | <.001 |
| Calcium ≥11 mg/dL | 21/219 (10) | 27/533 (5) | .03 |
| β2 microglobulin >5.5 μg/mL | 76/202 (38) | 133/463 (29) | .02 |
| Albumin ≤3.5 g/dL | 113/192 (59) | 252/520 (49) | .01 |
| Lactate dehydrogenase >222 U | 27/166 (16) | 59/445 (13) | .4 |
| BMPCs ≥50% | 129/231 (56) | 282/541 (52) | .3 |
| PCLI ≥1% | 50/101 (50) | 125/296 (42) | .2 |
| FISH | |||
| Trisomies | 75/165 (46) | 288/454 (63) | <.001 |
| 17p deletion/monosomy 17 | 18/165 (11) | 50/454 (11) | .97 |
| t(4;14) | 22/165 (13) | 32/454 (7) | .02 |
| t(14;16) | 8/165 (5) | 21/454 (5) | .9 |
| High-risk FISH | 46/165 (28) | 88/454 (19) | .03 |
| First-line treatment, n (%) | |||
| Doublet/triplet/other | 77/149/14 (32/62/6) | 299/247/54 (50/41/9) | <.001 |
| PI-based therapy | 158 (66) | 213 (36) | <.001 |
| ASCT in first-line therapy | 131 (55) | 280 (47) | .03 |
Unless otherwise noted, all data are n/N (%). Bold type indicates P < .05.
BMPCs, bone marrow plasma cells; PCLI, plasma cell labeling index; PI, proteasome inhibitor.